Cargando…

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection

Detalles Bibliográficos
Autores principales:	Lin, Qingqing, Zhu, Li, Ni, Zuowei, Meng, Haitao, You, Liangshun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141458/ https://www.ncbi.nlm.nih.gov/pubmed/32249185 http://dx.doi.org/10.1016/j.jmii.2020.03.015

Ejemplares similares

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
por: Zang, Jinkai, et al.
Publicado: (2020)

SARS-CoV-2 in perioperative medicine: lessons learnt
por: Ní Eochagáin, Aisling, et al.
Publicado: (2021)

Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
por: Uriu, Keiya, et al.
Publicado: (2021)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
por: Wang, Guo-Lin, et al.
Publicado: (2021)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020)

Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies
por: Hu, Jie, et al.
Publicado: (2021)

Cross-neutralization of SARS-CoV-2 Kappa and Delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
por: Cheng, Lin, et al.
Publicado: (2021)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants
por: Evans, John P., et al.
Publicado: (2022)

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1
por: van Doremalen, Neeltje, et al.
Publicado: (2020)

Duration of Culturable SARS-CoV-2 in Hospitalized Patients with Covid-19
por: Kim, Min-Chul, et al.
Publicado: (2021)

Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination
por: Yu, Xiaoqi, et al.
Publicado: (2022)

Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients
por: Gavriilaki, Eleni, et al.
Publicado: (2022)

Kinetics and seroprevalence of SARS-CoV-2 antibodies in children
por: Roarty, Cathal, et al.
Publicado: (2021)

The presence of SARS-CoV2 antibodies in MS patients
por: Wallach, Asya I., et al.
Publicado: (2021)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
por: Yu, Sicong, et al.
Publicado: (2021)

Sunitinib reduces the infection of SARS-CoV, MERS-CoV and SARS-CoV-2 partially by inhibiting AP2M1 phosphorylation
por: Wang, Pei-Gang, et al.
Publicado: (2020)

SARS-CoV-2 antibody response duration and neutralization following natural infection
por: Dukes, Christopher W, et al.
Publicado: (2023)

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients
por: Li, Yang, et al.
Publicado: (2020)

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 in people living with HIV
por: Yamamoto, Shinya, et al.
Publicado: (2021)

Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients
por: Del Zompo, Fabio, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Nazemipour, Maryam, et al.
Publicado: (2021)

Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran
por: Ghafari, Mahan, et al.
Publicado: (2021)

Immunoassays for anti-SARS-CoV-2 antibodies: recent insights
por: Van Elslande, Jan, et al.
Publicado: (2021)

Antibody-mediated neutralization of SARS-CoV-2
por: Gruell, Henning, et al.
Publicado: (2022)

Neutralizing antibodies for SARS-CoV-2 infection
por: Berenguer, Juan
Publicado: (2022)

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
por: Rössler, Annika, et al.
Publicado: (2022)

Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
por: Yu, Jingyou, et al.
Publicado: (2022)

Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
por: Zhao, Xin, et al.
Publicado: (2022)

Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6
por: Hachmann, Nicole P., et al.
Publicado: (2022)

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
por: Lv, Zhe, et al.
Publicado: (2020)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
por: Wang, Pengfei, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Monkeypox genomic surveillance will challenge lessons learned from SARS-CoV-2
por: Pfaff, Florian, et al.
Publicado: (2022)

SARS-CoV-2 shedding and infectivity
por: Atkinson, Barry, et al.
Publicado: (2020)

The proximal origin of SARS-CoV-2
por: Andersen, Kristian G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n7gtm6db12kgrn3isk8g7gd4ts